- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Collagen fibrils.
Displaying page 1 of 1.
EudraCT Number: 2017-004806-17 | Sponsor Protocol Number: PQ-313-002 | Start Date*: 2018-05-18 | |||||||||||
Sponsor Name:Wings Therapeutics Inc. | |||||||||||||
Full Title: A first in human, double-blind, randomized, intra-subject placebo-controlled, multiple dose study of QR-313 evaluating safety, proof of mechanism, preliminary efficacy and systemic exposure in subj... | |||||||||||||
Medical condition: Recessive Dystrophic Epidermolysis Bullosa (RDEB) due to mutation(s) in exon 73 of the COL7A1 gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) DE (Prematurely Ended) CZ (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004592-74 | Sponsor Protocol Number: HOLOGENE7(HTA-HG7-01) | Start Date*: 2016-06-01 |
Sponsor Name:Holostem Terapie Avanzate s.r.l. | ||
Full Title: PROSPECTIVE, OPEN LABEL, UNCONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF AUTOLOGOUS CULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED WITH A GAMMA-RETR... | ||
Medical condition: RDEB is characterized by generalized skin blistering, erosions, crusts, atrophic scarring, onychodystrophy and loss of nails, mutilating pseudosyndactyly of hands and feet, as well as oral cavity l... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004884-19 | Sponsor Protocol Number: LENTICOL-F | Start Date*: 2016-05-24 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: Phase I study of lentiviral-mediated COL7A1 gene-modified autologous fibroblasts in adults with recessive dystrophic epidermolysis bullosa (RDEB) | |||||||||||||
Medical condition: Recessive Dystrophic Epidermolysis Bullosa | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003537-18 | Sponsor Protocol Number: HYDRA-02 | Start Date*: 2023-01-13 | |||||||||||
Sponsor Name:Medizinische Universität Graz | |||||||||||||
Full Title: Assessment of the Tissue Hydraulic Resistance at the Site of Subcutaneous Insulin Infusion and Its Relation to Subcutaneous Insulin Absorption | |||||||||||||
Medical condition: Diabetes Mellitus type 1 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000605-72 | Sponsor Protocol Number: CB+MSCforEB | Start Date*: 2014-02-06 |
Sponsor Name:Universitair Medisch Centrum Utrecht | ||
Full Title: Unrelated cord blood transplantation after reduced toxicity conditioning with mesenchymal stromal cell co-infusion in patients with severe epidermolysis bullosa | ||
Medical condition: The source population consists of patients referred to or within the UMC Groningen because they have diagnosed clinically and genetically severe generalized RDEB. | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000606-37 | Sponsor Protocol Number: MesenSistem-EB | Start Date*: 2017-11-16 |
Sponsor Name:Fundación para la Investigación Biomédica Hospital Universitario La Paz | ||
Full Title: Safety and preliminary efficacy study of infusing mesenchymal stem cells derived from bone marrow for treating Recessive Dystrophic Epidermolysis Bullosa. | ||
Medical condition: Recessive Dystrophic Epidermolysis Bullosa | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2023-000283-62 | Sponsor Protocol Number: KB103-001 | Start Date*: 2023-03-21 | |||||||||||
Sponsor Name:Krystal Biotech | |||||||||||||
Full Title: A Phase I/II Study of KB103, a Non-Integrating, Replication-Incompetent HSV Vector Expressing the Human Collagen VII Protein, for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) | |||||||||||||
Medical condition: Dystrophic Epidermolysis Bullosa | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
